GlassScriptPhysician profile
Melissa Cupid
NPI 1982809133
$3,211.46
in general payments reported to CMS, 2019-2025
34 companies · $65.89 in 2025
The $65.89 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $533 · 2021: $461 · 2022: $741 · 2023: $520 · 2024: $68.05 · 2025: $65.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $525.06 | 2019-2023 | Farxiga, Breztri |
| Pfizer INC. | $386.12 | 2019-2020 | |
| Novo Nordisk INC | $314.13 | 2021-2025 | Saxenda, Wegovy, Ozempic |
| Amarin Pharma, INC. | $243.62 | 2020 | |
| Lilly USA, LLC | $214.87 | 2019-2023 | Jardiance, Trulicity, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $201.93 | 2021-2023 | |
| Lupin INC. | $184.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.63 | 2021-2023 | Xifaxan |
| Amgen INC. | $108.09 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $93.24 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.92 | 2019-2023 | Jardiance |
| Abbott Laboratories | $71.05 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $49.25 | 2023 | Nuedexta |
| Sumitomo Pharma America, INC. | $46.94 | 2023 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $46.59 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.26 | 2022-2024 | Verquvo, Belsomra, M-M-R II |
| Shire North American Group INC | $39.74 | 2019 | |
| Glaxosmithkline, LLC. | $39.40 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $37.10 | 2022-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $33.24 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $31.47 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $30.18 | 2024 | Veozah |
| Janssen Biotech, INC. | $29.34 | 2019 | |
| Hikma Pharmaceuticals USA | $28.83 | 2023 | Ryaltris, Mitigare, Kloxxado |
| Sunovion Pharmaceuticals INC. | $26.78 | 2022 | |
| Alkermes, INC. | $25.03 | 2025 | Vivitrol |
| Xeris Pharmaceuticals, INC. | $23.54 | 2025 | Gvoke Hypopen |
| Medtronic, INC. | $22.55 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.95 | 2021 | |
| Biogen, INC. | $19.47 | 2019 | |
| Mylan Specialty L.P. | $18.70 | 2023 | Yupelri |
| Genentech USA, INC. | $18.39 | 2019 | |
| Eisai INC. | $14.45 | 2021 | |
| G Medical Diagnostic Services, INC. | $11.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Cupid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.